Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Other financing activities (2021 - 2022)

Biote's quarterly Other financing activities came in at -$4.3 million in Q4 2022, down 220.82% year-on-year from $3.6 million in Q4 2021, and down 200.0% quarter-over-quarter from $4.3 million in Q3 2022.

Biote has reported Other financing activities for 2 years, with the latest figure at -$4.3 million in Q4 2022.

  • For the quarter ending Q4 2022, Other financing activities fell 220.82% year-over-year to -$4.3 million; the trailing twelve-month figure through Dec 2022 stood at $4.0 million (up 2.41% YoY), and the FY2022 full-year result was $4.0 million, up 2.41% from the prior year.
  • Other financing activities for Q4 2022 stood at -$4.3 million, down from $4.3 million in the prior quarter.
  • The five-year high for Other financing activities was $4.3 million in Q3 2022, with the low at -$4.3 million in Q4 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 Biote 61.29 Mn 64.11 Mn 30.95 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 -4.31 Mn
Dec 31, 2022 -4.31 Mn
Sep 30, 2022 4.31 Mn
Sep 30, 2022 4.31 Mn
Jun 30, 2022 2.46 Mn
Jun 30, 2022 2.46 Mn
Mar 31, 2022 1.58 Mn
Mar 31, 2022 1.58 Mn
Dec 31, 2021 3.56 Mn
Dec 31, 2021 3.56 Mn
Jun 30, 2021 48,347.00
Jun 30, 2021 48,347.00
Mar 31, 2021 329,614.00
Mar 31, 2021 329,614.00